Fundamental view – data vs expectations
The post‑hoc read‑out of the PoC 1 trial was markedly stronger than the original interim results disclosed last quarter. In the initial briefing the company reported a modest safety signal and a non‑significant trend toward efficacy, which had already been priced in and kept the stock near the $1.20 – $1.30 range. The new analysis, however, uncovers a statistically significant improvement in the primary endpoint (≈ 30 % relative gain versus control) and a cleaner safety profile. Analysts had been penciling in a “baseline‑only” outcome, so the upgraded efficacy signal is a positive surprise that lifts the consensus target price by roughly 10‑12 % and pushes sentiment up from neutral to mildly bullish (current sentiment index 30).
Technical and trading implications
On the chart, AMIX broke above its 20‑day EMA and retested the prior resistance at $1.45, forming a bullish flag that now sits on a volume surge of ~ 2× the average daily flow. The breakout coincides with the post‑hoc release, suggesting the market is re‑rating the stock rather than merely short‑term speculation. A prudent trade setup would be to buy on a pull‑back to the 20‑day EMA (around $1.38‑$1.40) with a stop just below the 50‑day EMA (~$1.30). The upside target can be set at the recent high of $1.68, offering a risk‑reward of roughly 2:1. Conversely, traders who are already long could consider scaling out half the position at $1.55 to lock in gains while staying exposed to the upside if further data (e.g., Phase II) confirms the PoC 1 trend.